tiprankstipranks
Advertisement
Advertisement

Anika Therapeutics reports Q1 EPS 27c vs.(6c) last year

Reports Q1 revenue $29.6M vs. $26.2M last year. Reports total company revenue grew 13%, driven by commercial channel strength and favorable OEM channel order timing. “Our strategic transformation and organizational realignment is yielding results and driving improved profitability and efficiencies throughout the organization,” said CEO Steve Griffin.

Claim 55% Off TipRanks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1